Cinqair (reslizumab; Teva) Drug Analysis Market Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Cinqair" drug pipelines has been added to ResearchAndMarkets.com's offering.

Drug Overview

Cinqair (reslizumab; Teva) is a humanized monoclonal antibody which targets interleukin (IL)-5. IL-5 has been shown to play a key role in the maturation, growth, and chemotaxis of eosinophils, which are inflammatory white blood cells implicated in a number of allergic diseases, including asthma. Cinqair gained US and EU approvals for use in asthma in an IV formulation in March 2016 and August 2016, respectively. Teva is also developing a subcutaneous formulation of Cinqair, which is in Phase III.

Key Topics Covered:

1 Product Profiles

  • Cinqair: Asthma

List of Figures

Figure 1: The author's drug assessment summary of Xolair in asthma

Figure 2: Xolair sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 3: Cinqair sales for asthma across the US and five major EU markets, by country, 2017-26

List of Tables

Table 1: Cinqair drug profile

Table 2: Cinqair pivotal Phase III data in asthma

Table 3: Cinqair sales for asthma across the US and five major EU markets, by country ($m), 2017-26

Companies Mentioned

  • Teva

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ls7wrw/cinqair?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Asthma Drugs